This Phase III study compares the recurrence-free survival as well as overall survival of patients with renal cell carcinoma receiving everolimus or placebo after full surgical resection and who have no residual or metastatic disease.
SAHA is a HDAC inhibitor. SAHA may also block angiogenic signaling by inhibiting the VEGF receptors expression and also reduce circulating levels of inflammatory cytokines. In this study SAHA is administered with Hydroxychloroquine in patients with advanced solid tumors
Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor. Patients with renal cell carcinoma who have received no prior systemic therapy for mRCC will be randomized to receive Tivozanib or Sunitinib for 12 weeks after what they will cross over for the other study drug they did not receive during the first 12 weeks.